Innoviva (INVA) Non-Current Deferred Tax Liability (2022 - 2026)
Innoviva's (INVA) quarterly Non-Current Deferred Tax Liability came in at $72.8 million in Q1 2026, up 129.08% on a QoQ basis from $31.8 million in Q4 2025.
Innoviva (INVA) Non-Current Deferred Tax Liability (2022 - 2026) Analysis & Trends
Innoviva (INVA) has 5 years of Non-Current Deferred Tax Liability data on file, last reported at $72.8 million in Q1 2026.
- Quarterly Non-Current Deferred Tax Liability changed N/A year-over-year to $72.8 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $72.8 million (changed N/A YoY) and the FY2025 annual result came in at $31.8 million, changed N/A from the prior year.
- Non-Current Deferred Tax Liability advanced to $72.8 million in Q1 2026, from $31.8 million in the prior quarter.
- In the past five years, Non-Current Deferred Tax Liability ranged from a high of $72.8 million in Q1 2026 to a low of $563000.0 in Q4 2023.
- A 5-year average of $20.0 million and a median of $5.6 million in 2022 frame the typical range for Non-Current Deferred Tax Liability.
- Annual changes were most pronounced in 2023 — Non-Current Deferred Tax Liability plunged 90.24% — and 2024, when it retreated 29.4%.
- Tracing INVA's Non-Current Deferred Tax Liability over 5 years: stood at $5.8 million in 2022, then sank by 90.24% to $563000.0 in 2023, then jumped by 576.2% to $3.8 million in 2024, then soared by 735.12% to $31.8 million in 2025, then soared by 129.08% to $72.8 million in 2026.
- The last three Non-Current Deferred Tax Liability figures came in at $72.8 million (Q1 2026), $31.8 million (Q4 2025), and $3.8 million (Q1 2024), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn |
| 10 | Innoviva | 1.54 Bn | 968.79 Mn | 90.62 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 36.74 Mn |
| Jun 30, 2026 | 36.74 Mn |
| Mar 31, 2026 | 72.83 Mn |
| Mar 31, 2026 | 72.83 Mn |
| Dec 31, 2025 | 31.79 Mn |
| Dec 31, 2025 | 31.79 Mn |
| Mar 31, 2024 | 3.81 Mn |
| Mar 31, 2024 | 3.81 Mn |
| Dec 31, 2023 | 563,000.00 |
| Dec 31, 2023 | 563,000.00 |
| Mar 31, 2023 | 5.39 Mn |
| Mar 31, 2023 | 5.39 Mn |
| Dec 31, 2022 | 5.77 Mn |
| Dec 31, 2022 | 5.77 Mn |